Analysis Of Income And Expense [Abstract]

Sopharma Trading AD - Filing #6022483

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31
Analysis of income and expense [abstract]
Material income and expense [abstract]
Write-downs (reversals of write-downs) of property, plant and equipment [abstract]
Impairment loss recognised in profit or loss, property, plant and equipment	—	—	- BGN	—	—	—	—	—	—	—	—	21 611 BGN	—	—
Finance income (cost)	—	—	10 801 BGN	—	—	—	—	—	—	—	—	6 337 BGN	—	—
Other operating income (expense)	—	—	7 716 BGN	—	—	—	—	—	—	—	—	8 903 BGN	—	—
Expenses by nature [abstract]
Raw materials and consumables used	—	—	10 703 BGN	—	—	—	—	—	—	—	—	10 536 BGN	—	—
Services expense	—	—	22 323 BGN	—	—	—	—	—	—	—	—	17 247 BGN	—	—
Classes of employee benefits expense [abstract]
Employee benefits expense	—	—	92 804 BGN	—	—	—	—	—	—	—	—	83 095 BGN	—	—
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]
Depreciation and amortisation expense [abstract]
Depreciation and amortisation expense	—	—	32 071 BGN	—	—	—	—	—	—	—	—	29 984 BGN	—	—
Other expenses, by nature	—	—	5 345 BGN	—	—	—	—	—	—	—	—	5 141 BGN	—	—
Disclosure of attribution of expenses by nature to their function [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of attribution of expenses by nature to their function [abstract]
Disclosure of attribution of expenses by nature to their function [line items]
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	- BGN	- BGN	28 561 BGN	28 553 BGN	- BGN	- BGN	8,000 BGN	- BGN	- BGN	- BGN	- BGN	9 645 BGN	9 574 BGN	71,000 BGN